## 1 Introduction  
Antibiotic-resistant infections are a growing global problem for primary care and hospital medicine. They are a therapeutic challenge and a considerable cost to social security systems [1]. Every year there are new strains resistant to antibiotics, while pan-resistant strains pose a particular threat [2]. In the next 30 years, there is a danger that most known therapies will no longer be sufficiently effective against the most common bacterial infectious diseases [3]. From this perspective, infections caused by methicillin-resistant _Staphylococcus aureus_ (MRSA) are becoming particularly important. Currently, MRSA causes the majority of skin and soft tissue infections in the United States of America and about half of the European infections [4]. At the same time, MRSA infections are characterized by significantly higher mortality than infections caused by other _S. aureus_ isolates [5, 6]. This strain can cause systemic infections as well as superficial ones. It is mainly associated with hospital-acquired (HA)-MRSA, particularly affecting the elderly and immunocompromised people. In recent years, it has been observed that MRSA infections also affect healthy people, including professional athletes [7]. This fact emphasizes the importance of the problem and the epidemic potential of this strain. _S. aureus_ resistance can arise through natural selection or horizontal plasmid transfer [8, 9]. MRSA shows resistance to beta-lactam antibiotics except for a new class of cephalosporins with anti-MRSA activity, which is a significant difficulty in treatment. Currently, the principal medications used are ceftroline, ceftobiprole, glycopeptide, lipopeptide, and oxazolidinone antibiotics [4]. On the other hand, several new strains of MRSA have already been isolated and revealed resistance to antibiotics, even to those used so far such as vancomycin and teicoplanin [10]. It suggests the possibility of further, rapid development of resistance to current treatments. Faced with these issues, it will become necessary to find new alternatives--PACT. The beginning of PACT dates back to the early 20 th century when, thanks to the observations of [PERSON] and [PERSON], it was discovered that certain compounds under the influence of visible light are able to kill bacteria. As a result of further experiments, it was found that reactive oxygen species (ROS) were the factor determining the death of bacteria. In photodynamic therapy, the interaction of three separately non-toxic components is crucial: a photosensitizer (PS), molecular oxygen, and light with a wavelength appropriate to the PS used. The great benefits of this therapy is its multi-targeting nature, non-specificity, and non-invasiveness. Additional advantages of PACT include the possibility of combining it with other therapeutic methods, its non-interference with parallel pharmacological treatment (e.g., antibiotic therapy), the option of repeated irradiation, and its low side effects and high safety profile. Moreover, photodynamic therapy may in the coming decades become the answer to the problem of antibiotic resistance in superficial infections, including infections with multidrug-resistant bacteria. It is extremely important that microorganisms have not yet developed specific defence mechanisms against singlet oxygen--the basic factor responsible for antimicrobial activity. The main cause of PACT failure is usually not bacterial resistance but problems with the delivery of the photosensitizer. The PS is often unable to penetrate inside the cell, and external activity may be insufficient to kill microbes. This fact emphasizes that the search for new PSs with optimal properties and the development of the existing ones will be essential in the near future [11; 12; 13; 14; 15; 16]. The article presents an entirely new approach to MRSA eradication. A possible option is the combination of photodynamic therapy (PDT) with sonodynamic therapy (SDT) [17]. Rose bengal, RB (xanthenes), has been known for many years as a dye with potential medical use (Figure 1).